Health & Wellness
Alabama man becomes first in the state to be cured of sickle cell anemia
A Mobile, Alabama man is the first in the state to become sickle cell free through a clinical trial with National Institutes of Health.
A Mobile, Alabama man is the first in the state to become sickle cell free through a clinical trial.
For two years, Lynndrick Holmes says he underwent a gene therapy treatment at the National Institutes of Health (NIH) in Washington, D.C.
“It feels amazing,” he said. “I didn’t know how bad it was living with sickle cell until I got cured. Once I got cured, I was like, ‘I can’t believe I was living like that and I was expected to live out the rest of my life like that.'”, Holmes told WPMI.
According to NIH, the treatment involved taking stem cells from his bone marrow, fixing the gene that causes his cells to sickle and reinserting that gene using the H-I-V virus; minus the parts of the virus that cause infection. That last part of the process happens after patients undergo chemotherapy to prepare for the introduction of the new cells.
Holmes completed his therapy in March. Researchers hope the therapy will become a cure.
Those who suffer with sickle cell anemia deal with intense pain when red blood cells become “sickle-shaped.” They clog blood vessels and starve organs of oxygen.
Doctors say it takes about five years without complications to declare a patient “cured” of sickle cell.
According to the NIH, the trial has about 50 slots, most have been filled already. Two of those patients will undergo the therapy at University of Alabama at Birmingham.
CLICK HERE to learn more about treatments available at UAB.
----------------------------------------------------------
Connect with Unheard Voices on Twitter, Facebook, TikTok, Instagram, YouTube
Download the app on Google Play or ITunes.
----------------------------------------------------------
Unheard Voices Magazine is a news reporting platform covered under Copyright Disclaimer Under Section 107 of the Copyright Act 1976, allowance is made for "fair use" for purposes such as criticism, comment, news reporting, teaching, scholarship, and research.